Decades and dozens of drugs have passed, and most of them have failed, but the amyloid hypothesis does not go smoothly into the night.
While the world awaits the FDA’s decision on Biogen’s controversial aducanumab, a rival of Big Pharma says it now has data to support its own Alzheimer’s drug that eliminates amyloid.
Eli Lilly said on Monday that her beta-amyloid antibody, donanemab, reduced the rate of decline in patients with moderate Alzheimer’s in a randomized Phase II study. Patients who received the drug decreased 32% more than those who received placebo, as measured by standard diagnostic scales for the disease, said Lilly. The company said the results were statistically significant, but did not disclose a p-value.
Continue reading Endpoints with a free subscription
Unlock this story instantly and join more than 97,300 biopharmacology professionals reading Endpoints daily – and it’s free.